Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03374540 · ClinicalTrials.gov registry record
Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
A clinical trial of Nonvalvular Atrial Fibrillation, sponsored by Bayer.
- Completed
- Registry status
- 78,517
- Enrollment target
- 1
- Study location
NCT03374540: Completed study of Nonvalvular Atrial Fibrillation, sponsored by Bayer.
NCT03374540 is a study of Nonvalvular Atrial Fibrillation that has completed, run by Bayer. The registered enrollment target is 78,517 participants, below the 93,588-participant average among 5 other Nonvalvular Atrial Fibrillation trials with a reported enrollment target (16% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03374540, a study of Nonvalvular Atrial Fibrillation, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 78,517 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) across risk profiles and comorbidities that reflect everyday clinical practice. The primary objective in this study was to evaluate the combined end point of stroke or systemic embolism (SSE), and major bleeding in NVAF patients treated with rivaroxaban vs. VKA.
Conditions Studied
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Vitamin K antagonist (VKA)
Study Locations (1)
Washington
- Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases - Multiple Locations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78,517 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-08-30 |
What the finished NCT03374540 record still lists
NCT03374540 is an observational study that tracks outcomes without assigning an intervention. Its 78,517 participants enrollment target places it among the larger protocols in the corpus, below the 93,588-participant average among 5 other Nonvalvular Atrial Fibrillation trials with a reported enrollment target (16% lower).
The record links to 1 condition, with Nonvalvular Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT03374540 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT03374540 about?
NCT03374540 is a clinical study titled "Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients". The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) across risk profiles and comorbidities that reflect everyday clinical practice. The pri...
What is the current status of trial NCT03374540?
This trial is currently completed. The enrollment target is 78,517 participants. The study started on 2017-12-01. Estimated completion is 2019-08-30.
What conditions does trial NCT03374540 study?
This clinical trial studies the following conditions: Nonvalvular Atrial Fibrillation.
What interventions are being tested in trial NCT03374540?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Vitamin K antagonist (VKA) (DRUG).
Who is sponsoring clinical trial NCT03374540?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03374540 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonvalvular Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR)
RECRUITING · NA
-
The CONFORMAL Early Feasibility Study
ACTIVE NOT RECRUITING · NA
-
An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation
ACTIVE NOT RECRUITING · NA
-
Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation
COMPLETED
-
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00063063 · 80,000 participants
Generic Database of Very Low Birth Weight Infants
- NCT06625983 · 80,000 participants · NA
Use of a Colorectal Cancer Screening Decision Support Tool in Primary Care
- NCT05701111 · 80,800 participants · NA
Building Resilience at Schools: Emotional and Biological Assessment and Treatment of Traumatic Stress
- NCT02402244 · 75,000 participants
Project: Every Child for Younger Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI